Short-term treatment of uterine fibromyomas with danazol

Gynecologic and Obstetric Investigation

Volumn 47, Issue 4, 1999, Pages 258-262

  De Leo, Vincenzo ^a   La Marca, Antonio ^b   Morgante, Giuseppe ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b NONE

Author keywords

Danazol; Estradiol; Fibromyomas, uterine; Progesterone

Indexed keywords

DANAZOL; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HUMAN; HUMAN CELL; LUTEINIZING HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; STATISTICAL ANALYSIS; ULTRASOUND; UTERUS MYOMA; VOLUMETRY;

EID: 0033011106     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000010118     Document Type: Article

References (27)

1. Buttram VC Jr, Reiter RC: Uterine leiomyomata: Etiology, symptomatology and management. Fertil Steril 1981;36:433-445.
2. Torpin R, Pund E, Peeples WJ: The etiologic and pathologic factors in a series of 1741 fibromyomas of the uterus. Am J Obstet Gynecol 1942;103:246-251.
3. Berkeley AS, DeCherney AH, Polan ML: Abdominal myomectomy and subsequent infertility. Surg Gynecol Obstet 1983;156:319-322.
4. Vessey MP, Villartd-Mackintosh L, McPherson K, Coulter C, Yeates D: The epidemiology of hysterectomy: Findings in a large cohort study. Br J Obstet Gynaecol 1992;99:402-407.
5. Farrer-Brown G, Beilby JOW, Tarbit MH: Venous changes in the endometrium of myomatous uteri. Obstet Gynecol 1971;38:743-751.
6. Goldzieher JW, Maqueo M, Ricaud L, Aguilar JA, Canales E: Induction of degenerative changes in uterine myomas by high-dosage progestin therapy. Am J Obstet Gynecol 1966;96: 1078-1087.
7. Katz VL, Dotters DJ, Droegemeuller W: Complications of uterine leiomyomas in pregnancy. Obstet Gynecol 1989;73:593-596.
8. Filicori M, Hall DA, Loughlin JS, Rivier S, Vale W, Crowley WF: A conservative approach to the management of uterine leiomyomata: Pituitary desensitization by a luteinizing hormone-releasing hormone analogue. Am J Obstet Gynecol 1983;147:726-727.
9. Countinho EM, Boulanger GA, Goncalves MT: Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone. Am J Obstet Gynecol 1986; 155:761-765.
10. Buchi K, Keller PJ: Estrogen receptors in normal and myomatous human uteri. Gynecol Obstet Invest 1980;11:59-63.
11. Wilson EA, Yang F, Rees D: Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol 1980;55:20-23.
12. Buchi K, Keller PJ: Cytoplasmic progestin receptors in myomal and myometrial tissues. Acta Obstet Gynecol Scand 1983;62:487-492.
13. Tamaya T, Fujimoto J, Okada H: Comparison of cellular levels of steroid receptors in uterine leiomyomata and myometrium. Acta Obstet Gynecol Scand 1985;64:307-309.
14. Kornyei J, Csermely T, Szekely JA, Vertes M: Two types of nuclear oestradiol binding sites in human myometrium and leiomyoma during the menstrual cycle. Exp Clin Endocrinol 1986; 87:256-264.
15. Friedman AJ, Daly M, Juneau-Norcross M, Rein MS, Fine C, Gleason R, Leboff M: A prospective, randomized trial of a gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin 'add-back' regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 1993;76:1439.
16. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS: Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76:513-517.
17. McDonnell DP, Goldman ME: RU486 exerts antiestrogenic activities through a novel receptor A form-mediated mechanism. J Biol Chem 1994;269:11945-11949.
18. Dmowski WP, Cohen MR: Treatment of endometriosis with an antigonadotropin, danazol: A laparoscopic and histologic evaluation, Obstet Gynecol 1975;46:174-177.
19. Barbieri RL, Lee H, Ryan KJ. Danazol binding to rat androgen, glucocorticoid, progesterone and estrogen receptors. Fertil Steril 1979;31: 182-186.
20. Letterie GS, Coddington CC, Winkel CA, Shawker TH, Loriaux DL, Collins RL: Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leimyomata: Long-term follow-up. Fertil Steril 1989;51:951-956.
21. Rein MS, Barbieri RL, Friedman AJ: Progesterone: A critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995; 172:14-19.
22. Adams AD, Hild-Petito S, Donnely K, Fazleabas AT: Regulation of estrogen (E) and progestin (P) receptors in leiomyomas during the cycle and leuprolide acetate treatment; in Proceedings of the Forty-Ninth Annual Meeting of the American Fertility Society, Montreal, Quebec, Canada, October 11-14, 1993. Montreal, American Fertility Society, 1993.
23. Tiltman AJ: The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 1985;4:89-96.
24. Kawaguchi K, Fujii S, Konishi I, Okamura H, Mori T: Ultrastructural study of cultured smooth muscle cells from uterine leiomyoma and myometrium under the influence of sex steroids. Gynecol Oncol 1985;21:32-41.
25. Franchimont P, Cramilion C: The effects of danazol on anterior pituitary function. Fertil Steril 1977;28:814-818.
26. Chamnes GC, Asch RH, Pauerstein CJ: Danazol binding and translocation of steroid receptors. Am J Obstet Gynecol 1980;136:426-431.
27. De Leo V, Morgante G, Lanzetta D, D'Antona D, Bertieri RS: Danazol administration after gonadotrophin-releasing hormone analogue reduces rebound of uterine myomas. Hum Reprod 1997;12:357-360.